Market Place
Sourcing Support
MAIA Biotech Gets FDA Rare Pediatric Disease Designation for THIO
16 Dec 2024 //
BUSINESSWIRE
MAIA Expands Regeneron Supply Deal for NSCLC Phase 2 Trial
03 Dec 2024 //
BUSINESSWIRE
MAIA Biotech Announces Director`s Participation in Private Placement
07 Nov 2024 //
BUSINESSWIRE
MAIA Biotechnology Presents THIO-101 Data at SITC 2024
05 Nov 2024 //
BUSINESSWIRE
MAIA Biotechnology Announces $2.44 Million Private Placement
28 Oct 2024 //
BUSINESSWIRE
MAIA Biotechnology Announces Poster Presentation At ENA 2024
15 Oct 2024 //
BUSINESSWIRE
MAIA Announces Positive THIO Phase 2 Survival Updates
10 Sep 2024 //
BUSINESSWIRE
MAIA Biotechnology to Present Phase 2 Data at H.C. Wainwright Conference
04 Sep 2024 //
BUSINESSWIRE
MAIA Biotechnology Updates Phase 2 Trial Of Cancer Treatment Agent
23 Jul 2024 //
BUSINESSWIRE
MAIA Highlights 2024 Achievements, Anticancer Progress
07 Jun 2024 //
BUSINESSWIRE
FDA Telomerase Approval Shows Viability Of MAIA`s Telomere Approach
07 Jun 2024 //
BUSINESSWIRE
MAIA Highlights Novel Anticancer Agent Progress In 2024
06 Jun 2024 //
BUSINESSWIRE
MAIA Bio: THIO Efficacy In Non-Small Cell Lung Cancer
04 Jun 2024 //
BUSINESSWIRE
MAIA Biotechnology to Present at the BIO International Convention 2024
17 May 2024 //
BUSINESSWIRE
MAIA Biotech Abstract Accepted For ASCO 2024 Poster
16 May 2024 //
BUSINESSWIRE
MAIA Announces Director`s Share Purchase In Private Placement
30 Apr 2024 //
BUSINESSWIRE
MAIA Bio Director Stan Smith Ph.D. Participates in Private Placement
29 Apr 2024 //
BUSINESSWIRE
MAIA Biotechnology Announces $1.00 Million Private Placement
23 Apr 2024 //
BUSINESSWIRE
MAIA Biotechnology to Present at Two Investor Conferences in April 2024
05 Apr 2024 //
BUSINESSWIRE
MAIA Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero
28 Mar 2024 //
BUSINESSWIRE
MAIA Announces Share Purchase by Director Adelina Louie in Private Placement
26 Mar 2024 //
BUSINESSWIRE
MAIA Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap
21 Mar 2024 //
BUSINESSWIRE
MAIA Biotechnology to Participate in the 36th Annual ROTH Conference
07 Mar 2024 //
BUSINESSWIRE
MAIA Biotechnology Announces Strong Efficacy of THIO
06 Mar 2024 //
BUSINESSWIRE
MAIA and Nationwide Children’s Hospital Announce Presentation of THIO
06 Mar 2024 //
BUSINESSWIRE
MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates
05 Mar 2024 //
BUSINESSWIRE
MAIA Appoints Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor
27 Feb 2024 //
GLOBENEWSWIRE
MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial
22 Feb 2024 //
GLOBENEWSWIRE
MAIA Announces Publication on Effects of THIO for Small Cell Lung Cancer
07 Feb 2024 //
BUSINESSWIRE
MAIA Biotechnology Announces Publication of International PCT Patent Application
24 Jan 2024 //
BUSINESSWIRE
MAIA Bio Provides Positive Phase 2 Clinical Updates for Anticancer Agent
17 Jan 2024 //
BUSINESSWIRE
MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024
05 Jan 2024 //
BUSINESSWIRE
MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial
19 Dec 2023 //
BUSINESSWIRE
MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering
17 Nov 2023 //
BUSINESSWIRE
MAIA Biotechnology Announces $4 Million Registered Direct Offering
15 Nov 2023 //
BUSINESSWIRE
FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO
10 Nov 2023 //
BUSINESSWIRE
MAIA Biotechnology Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
BUSINESSWIRE
MAIA Biotech Reveals Higher Anticancer Potency of Telomere-Targeting Compounds
30 Oct 2023 //
BUSINESSWIRE
MAIA Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer
24 Oct 2023 //
BUSINESSWIRE
MAIA Bio to Present Preliminary Safety Data from THIO-101 Phase 2 Trial
19 Oct 2023 //
BUSINESSWIRE
MAIA Bio to Present Findings for Second Generation THIO Program
17 Oct 2023 //
BUSINESSWIRE
MAIA Biotechnology Reveals New Data Showing THIO’s Potent Anticancer Activity
12 Oct 2023 //
BUSINESSWIRE
MAIA Biotechnology Announces Potent Anticancer Activity of THIO in Gliomas
10 Oct 2023 //
BUSINESSWIRE
MAIA Biotechnology Accelerates Enrollment in THIO-101 Phase II Clinical Trial
10 Oct 2023 //
BUSINESSWIRE
MAIA Biotechnology Announces FDA Clearance of IND Application for THIO
03 Oct 2023 //
BUSINESSWIRE
MAIA Biotechnology Announces Share Repurchase Program
28 Sep 2023 //
BUSINESSWIRE
MAIA Biotechnology Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
BUSINESSWIRE
MAIA Reports Updates on Disease Control Rates for THIO-101 Phase 2 Trial
11 Jul 2023 //
BUSINESSWIRE
MAIA Reports Updates on Preliminary Survival Data for THIO-101 Phase 2 Trial
10 Jul 2023 //
BUSINESSWIRE
MAIA Biotechnology Announces Updates in Enrollment in Phase II Clinical Trial
20 Jun 2023 //
BUSINESSWIRE
MAIA Bio Files Second Patent For New Telomere-Targeting Molecules Program
07 Jun 2023 //
BUSINESSWIRE
MAIA Biotechnology Reports First Quarter 2023 Financial Results
08 May 2023 //
BUSINESSWIRE
MAIA Biotechnology, Inc. Announces Pricing of Public Offering
24 Apr 2023 //
BUSINESSWIRE
MAIA Biotechnology Announces Excellent Efficacy of THIO in Liver Cancer Models
18 Apr 2023 //
BUSINESSWIRE
MAIA Biotechnology to Present at AACR Annual Meeting 2023
12 Apr 2023 //
BUSINESSWIRE
MAIA Reports Data from THIO-101 PII Trial for Non-Small Cell Lung Cancer
11 Apr 2023 //
BUSINESSWIRE
MAIA Biotechnology Reports Full Year 2022 Financial Results
24 Mar 2023 //
BUSINESSWIRE
MAIA Biotechnology Announces No Exposure to Silicon Valley Bank
13 Mar 2023 //
BUSINESSWIRE
MAIA Biotechnology Advances New Telomere-Targeting Molecule Program
17 Jan 2023 //
BUSINESSWIRE
